Day: October 19, 2025

Dubai, Oct. 19, 2025 (GLOBE NEWSWIRE) — Vantage Drilling International Ltd. (the “Company”) announces the immediate termination of the contract for the Platinum Explorer for its approximately 260-day campaign. The termination is due to changes in economic sanctions applicable to the campaign, rendering the contract execution unlawful and therefore subject to termination. This information has been submitted pursuant to Section 5-12 of the Norwegian Securities Trading Act and MAR Article 17. The information was submitted for publication at 2025-10-19 at 7:30 CEST. About the Company Vantage Drilling International Ltd., a Bermuda exempted company, is an offshore drilling contractor. Vantage Drilling’s primary business is to contract drilling units, related equipment and work crews primarily on a dayrate basis to drill oil and...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC)1Most patients with mHSPC progress to metastatic castration-resistant prostate cancer, underscoring urgent need for new therapies that can reduce risk of progression in earlier disease settings2,3The safety profile and tolerability of Pluvicto in this third positive Phase III study were consistent with its established profile in PSMAfore and VISION trials1,4,5Novartis plans to submit to regulatory authorities by end of year; potential approval would double the number of patients eligible for Pluvicto and further establish its efficacy in metastatic prostate cancer settingsBasel, October 19, 2025 – Novartis...

Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m² LONDON and PHILADELPHIA, Oct. 19, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a unique oncology delivery platform, today announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin (FAP-Dox, AVA6000) to be presented at the 2025 European Society of Medical Oncology Annual...

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted by its partner, Shanghai Jeyou Pharmaceutical Co., Ltd. (Jeyou), formerly called Shanghai Jemincare Pharmaceutical Co., Ltd., in a premarket press release and webcast on Monday, October 20, 2025. RAPT will host a webcast conference call accompanied by a slide presentation on Monday, October 20, 2025 at 8:30 a.m. ET. To join the conference call via phone and participate...

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P). The analysis of acral melanoma patients from the IGNYTE clinical trial showed treatment with RP1 combined with nivolumab resulted in an objective response rate of 44% (8/18) with a median duration of response of 11.9 months (3.9, not reached). The safety profile was favorable with generally transient grade 1 and 2 treatment related adverse events. Acral melanoma is a rare and aggressive type of cutaneous...